News | September 27, 2017
Deciphera Pharmaceuticals Announces Pricing of Initial Public Offering
WALTHAM, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) — Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of its initial public offering of 7,500,000 shares of common stock at a public offering price of $17.00 per share for aggregate gross proceeds of $127,500,000. All of the shares of common stock are being offered by Deciphera. In addition, Deciphera granted the underwriters a 30-day option to purchase up to 1,125,000 additional shares of its common stock at the initial public offering price. The shares are scheduled to begin trading on the NASDAQ Global Select Market on September 28, 2017 under the ticker symbol “DCPH.” The offering is expected to close on October 2, 2017, subject to customary closing conditions.
J.P. Morgan and Piper Jaffray & Co. are acting as joint book-running managers for the offering. JMP Securities LLC is acting as lead manager and Nomura Securities International, Inc. is acting as a co-manager for the offering.
A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on September 27, 2017. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, or by telephone at (866) 803-9204, or Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN, 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Deciphera is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.
Gina Nugent, The Yates Network
Laura Perry or Sam Martin, Argot Partners
Laura@argotpartners.com or Sam@argotpartners.com
Christopher J. Morl, Chief Business Officer
Deciphera Pharmaceuticals, LLC